445 related articles for article (PubMed ID: 23415997)
21. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women.
Checa Vizcaíno MA; Corchado AR; Cuadri ME; Comadran MG; Brassesco M; Carreras R
Reprod Biomed Online; 2012 Jun; 24(6):606-10. PubMed ID: 22503276
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
23. [Fertility preserving methods in women with breast cancer before gonadotoxic therapy].
Halászová N; Crha I; Huser M; Weinberger V; Žáková J; Ješeta M; Lousová E; Filipinská E; Ventruba P
Ceska Gynekol; 2017; 82(4):287-292. PubMed ID: 28925272
[TBL] [Abstract][Full Text] [Related]
24. Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Shulman Y; Almog B; Kalma Y; Fouks Y; Azem F; Cohen Y
J Assist Reprod Genet; 2021 Mar; 38(3):743-750. PubMed ID: 33409757
[TBL] [Abstract][Full Text] [Related]
25. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
26. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
27. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy.
Das M; Shehata F; Son WY; Tulandi T; Holzer H
Hum Reprod; 2012 Aug; 27(8):2509-14. PubMed ID: 22617122
[TBL] [Abstract][Full Text] [Related]
28. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
29. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type.
Lefebvre T; Mirallié S; Leperlier F; Reignier A; Barrière P; Fréour T
Reprod Biomed Online; 2018 Aug; 37(2):201-207. PubMed ID: 29784618
[TBL] [Abstract][Full Text] [Related]
30. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
31. Ovarian sensitivity index is a better measure of ovarian responsiveness to gonadotrophin stimulation than the number of oocytes during in-vitro fertilization treatment.
Li HW; Lee VC; Ho PC; Ng EH
J Assist Reprod Genet; 2014 Feb; 31(2):199-203. PubMed ID: 24317853
[TBL] [Abstract][Full Text] [Related]
32. Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response.
Alvarez RM; Ramanathan P
Hum Reprod; 2018 Nov; 33(11):2051-2059. PubMed ID: 27370358
[TBL] [Abstract][Full Text] [Related]
33. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience.
Cardozo ER; Thomson AP; Karmon AE; Dickinson KA; Wright DL; Sabatini ME
J Assist Reprod Genet; 2015 Apr; 32(4):587-96. PubMed ID: 25595540
[TBL] [Abstract][Full Text] [Related]
34. A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response.
Bastu E; Buyru F; Ozsurmeli M; Demiral I; Dogan M; Yeh J
Eur J Obstet Gynecol Reprod Biol; 2016 Aug; 203():30-4. PubMed ID: 27236602
[TBL] [Abstract][Full Text] [Related]
35. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
Mohsen IA; El Din RE
Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
[TBL] [Abstract][Full Text] [Related]
36. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Oktay K; Hourvitz A; Sahin G; Oktem O; Safro B; Cil A; Bang H
J Clin Endocrinol Metab; 2006 Oct; 91(10):3885-90. PubMed ID: 16882752
[TBL] [Abstract][Full Text] [Related]
37. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
38. Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes.
Ben-Haroush A; Wertheimer A; Klochendler E; Sapir O; Shufaro Y; Oron G
Gynecol Endocrinol; 2019 Apr; 35(4):324-327. PubMed ID: 30596311
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
40. Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients.
Lin HT; Wu MH; Tsai LC; Chen TS; Ou HT
Front Endocrinol (Lausanne); 2021; 12():780392. PubMed ID: 35095758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
